Background and purpose Alemtuzumab, a monoclonal CD52 antibody, is a high‐efficacy disease‐modifying‐therapy in relapsing‐remitting multiple sclerosis (RRMS). Recently, intracerebral hemorrhage (ICH) was reported as a possible treatment‐related adverse event. Arterial hypertension during infusion was suggested as a potential cause, although platelet or endothelial dysfunction may also contribute. This study aimed to screen for occult hemorrhagic cerebral lesions after alemtuzumab treatment and to further elucidate risk factors. Methods We included 30 RRMS patients who received alemtuzumab treatment at Ghent University Hospital or Sint‐Jan Bruges Hospital. Retrospective data concerning vital signs, adverse effects and thrombocyte levels during treatment were collected. The occurrence of occult intracranial hemorrhagic lesions was assessed by magnetic resonance imaging with susceptibility‐weighted imaging (SWI). Results The mean (standard deviation SD) systolic blood pressure (SBP) during the morning, afternoon and evening was 120 (3.38) mmHg during first administration and 114 (4.40) mmHg during second administration (N = 13). There was no significant increase in SBP when comparing morning, afternoon and evening per day, nor was there a significant difference in daily mean SBP between consecutive administration days. Thrombocyte count during treatment cycles ranged between 107 × 109/L and 398 × 109/L, with a mean (SD) absolute reduction of 59.3 × 109/L (50.65) or a mean (SD) relative reduction of 25.0 (12.84)% (N = 20). No patient had ICH, nor did SWI show any cerebral microbleeds or other hemorrhagic lesions post‐treatment (N = 23). Conclusions In our patient population, alemtuzumab treatment was not associated with arterial hypertension, ICH or occult microbleeds. Possible differences in administration regimen (ambulatory vs. in‐hospital setting) and patient population (cardiovascular risk) might explain an increased risk in different populations. Arterial hypertension and intracerebral hemorrhages were recently reported as adverse events in alemtuzumab‐treated multiple sclerosis patients. In our cohort, retrospective analysis did not show a significant increase in systolic blood pressure during alemtuzumab infusions. Magnetic resonance imaging with susceptibility‐weighted imaging (SWI) sequences did not show any signs of hemorrhage or (occult) microbleeds post‐treatment.